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ABSTRACT
The high recurrence rate and the low overall survival in ovarian
cancer suggest that a more specific therapeutic approach in
addition to conventional treatment is required. Translational
and clinical research is investigating new molecular targets in
order to find an alternative way to affect tumor growth and to
minimize the overlap of toxicity of antiblastic agents. Given its
implication in many cellular activities including regulation of
cell growth, motility, survival, proliferation, protein synthesis,
autophagy, transcription, as well as angiogenesis, PI3K/AKT/
mTOR is one of the most investigated intracellular signaling
pathways. A dis-regulation of this pathway has been shown
in several tumors, including ovarian cancer. In this setting,
mTor proteins represent a potential target for inhibitors,
which could ultimately play a pivotal role in counteracting cel-
lular proliferation. Recently, mTor inhibitors have been ap-
proved in the treatment of pancreatic neuroendocrine tu-
mors, mantle cell lymphoma and renal cancer. Clinical trials
have assessed the safety of these drugs in ovarian cancer pa-
tients. Ongoing phase I and II studies are evaluating the onco-
logic outcome of mTor inhibitor treatment and its effect in
combination with conventional chemotherapy and target
agents.
ZUSAMMENFASSUNG
Die hohe Rückfallquote und die allgemeine niedrige Gesamt-
überlebensrate beim Ovarialkrebs weisen darauf hin, dass ne-
ben der herkömmlichen Behandlung zusätzlich eine spezi-
fischere Therapie benötigt wird. In der translationalen und kli-
nischen Forschung wird derzeit nach alternativen molekula-
ren Zielstrukturen gesucht, die einerseits das Tumorwachs-
tum aufhalten und andererseits die überlappende Toxizität
von wachstumshemmenden Wirkstoffe minimieren könnten.
Da PI3K/AKT/mTOR viele Zellfunktionen steuern, u. a. die Re-
gulierung des Zellwachstums, Motilität, Überleben, Prolifera-
tion, Proteinsynthese, Autophagozytose, Transkription und
Angiogenese, gehören sie zu den meist untersuchten intrazel-
lulären Signalwegen. Eine Deregulierung dieses Signalweges
wurde bei einigen Tumoren festgestellt, darunter auch für
das Ovarialkarzinom. Vor diesem Hintergrund könnten mTor-
Proteine potenzielle Ziele für Inhibitoren sein, die dann eine
Schlüsselrolle bei der Hemmung der Zellproliferation spielen
könnten. Vor Kurzem wurden mTor-Inhibitoren zur Behand-
lung von neuroendokrinen Tumoren der Bauchspeicheldrüse,
Mantelzell-Lymphomen und Nierenkrebs zugelassen. Kli-
nische Studien haben die Sicherheit dieser Medikamente in
Patientinnen mit Eierstockkrebs untersucht. Aktuell werden
Phase-I und ‑II-Studien durchgeführt, um die onkologischen
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Ergebnisse nach einer Behandlung mit mTOR-Inhibitoren und
die Auswirkungen dieser Therapie in Kombination mit kon-
ventioneller Chemotherapie und Target-Wirkstoffen zu be-
werten.
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In the past decades a significant amount of research has focused
on ovarian cancer. The better understanding of the molecular pro-
cesses that occur in the cancerous cells, the receptors expressed
on the cancerous cells and molecular mechanisms involved in car-
cinogenesis and tumor progression has led to the development
and use of new targeted therapies [1–15]. Concomitantly,
through the improvement of surgical techniques and medical
support of the patients the optimal cytoreduction rates have pro-
gressively increased [16–22]. Unfortunately, despite these efforts
and improvements ovarian cancer still remains the deadliest
gynecological cancer and it is estimated that, in the USA, approx-
imately 14180 women died of ovarian cancer in 2015 [23]. Its ag-
gressiveness is mostly related to the late presentation of the
symptoms. As a result, more than half of the diagnoses are made
at an advanced stage. The current standard treatment of ad-
vanced disease ovarian cancer consists in a radical surgery and by
systemic chemotherapy with carboplatin and paclitaxel, delivered
either adjuvantly or neoadjuvantly [24]. Thanks to the continuous
research and the development of new treatments, the prognosis
of women affected by ovarian cancer is better than it used to be.
However, with an overall survival of roughly 40% at five years, it is
far from satisfactory [25]. Furthermore, approximately 25% of the
patients will suffer a relapse within 6 months after completion of
their treatment [26]. Platinum-resistant recurrences are ex-
tremely difficult to treat and often lead to death in a short interval
of time. Hence, there is urgent need to find new therapeutic strat-
egies to improve the current clinical results.
Recently, particular attention has been paid to the molecular
aspects of ovarian cancer, in an attempt to better understand
and consequently treat the disease. Extensive genomic analysis
using molecular profiling performed by the Cancer Genome Atlas
helped in identifying some of the most common alterations in-
volving metabolic and signaling pathways in ovarian cancer [27].
Among them, the PI3K/Akt/mTor pathway is one of the most
investigated intracellular signaling pathways, given its implication
in many cellular activities including regulation of cell growth, mo-
tility, survival, proliferation, protein synthesis, autophagy, tran-
scription as well as angiogenesis [28]. Studies adopting compara-
tive genomic hybridization arrays have found PI3K/AKT/mTOR to
be the most frequently altered intracellular pathway in ovarian
cancer [29,30]. This is a complex pathway that integrates a num-
ber of upstream inputs ranging from growth factors (epidermal
growth factor, tumor growth factor etc.), tyrosine-kinase recep-
tors (insuline growth factor 1 receptor, epidermal growth factor
receptor, HER2) and other membrane receptors such as Met, or
RAS-mediated cross talk with the Ras-Raf-Mek-Erk pathway [31].
The interaction of the above mentioned compounds with PI3K ac-
tivates downstream effectors such as AKT and the mTORC1 com-
plex.1096 GOverview of the PI3K/Akt/mTor Pathway
PI3Ks are part of the lipid-kinases family, originally discovered in
the 1980s [32]. Based on their structure and substrate specificity,
PI3Ks have been categorized into 3 distinct classes: I–II and III.
Class I PI3Ks is divided into class IA and class IB based on the dif-
ferences in their activating receptors. In class IA PI3K are grouped
heterodimers consisting of a p85 regulatory subunit and a p110
catalytic subunit, which has 3 isomers (α, β and γ) respectively en-
coded by three distinct genes, PIK3CA, PIK3CB, and PIK3CD. Of
these, the most frequently mutated in human cancer appears to
be PIK3CA [33].
When bound to its ligands, PI3K results in the allosteric activa-
tion of the p110 catalytic subunit that finally leads to phosphoryl-
ation of phosphatidylinositol 4,5-bisphosphate (PIP2) into the ac-
tive second messenger PIP3, thus triggering the PDK1 proteins
and recruiting AKT to the plasma membrane. Phosphatase and
tensin homolog (PTEN) can specifically catalyze the dephosphory-
lation of the PI(3, 4, 5)P3, converting PI(3, 4, 5)P3 back to PI(4,
5)P2, thereby negatively regulating PI3K pathway [34]. A similar
negative regulation action is carried out by Inositol polyphosphate
4-phosphatase type 2 (INPP4B) that hydrolyzes PI(3, 4)P2. Conse-
quently, mutation or blockade of the above pathway can ulti-
mately lead to an independent cell growth and enhanced overall
motility, due to the lack of negative regulators of the PI3K/AKT/
mTOR cascade [35].
Activated AKT (also known as protein kinase B) regulates a
large number of downstream mediators, ultimately controlling
critical cell survival and metabolic processes [31]. It can activate
mTORC1 directly, by phosphorylating the Ser2448 or indirectly
by phosphorylating tuberous sclerosis complex 2 (TSC2). TSC1/
TSC2 (tuberous sclerosis complex proteins) work as an activating
protein for the Ras homolog enriched in brain (Rheb)-GTPase,
thus promoting the conversion of Rheb-GTP into its inactive GDP
form, which silences mTORC1 when accumulated [36]. By phos-
phorylating TSC2, AKT makes the complex TSC1/TSC2 inactive,
thus indirectly stimulating mTor kinase activity.
Mammalian target of rapamycin (mTor) is a serine/threonine
protein kinase, firstly identified in the budding yeast Saccharo-
myces cerevisiae during a test for resistance to the immunosup-
pressant drug rapamycin [37]. It performs its activities through 2
distinct complexes: mTORC1-Raptor and mTORC2-Rictor, which
have recently emerged as key regulators of the differentiation of
helper T cells [38].
When activated, mTORC1 phosphorylates ribosomal S6 ki-
nase-1 (S6K‑1) and eukaryote translation initiation factor 4E bind-
ing protein-1 (4EBP‑1), both pivotal translation-regulating factors.
The first one is implicated in translation of mRNA encoding for ri-
bosomal proteins and elongation factors crucial for passage from
G1 to S phase of the cell cycle. The second helps cell cycle pro-asparri ML et al. PI3K/AKT/mTOR Pathway in… Geburtsh Frauenheilk 2017; 77: 1095–1103
gression or angiogenesis through translation of mRNA encoding
for cyclin D1, c-Myc, and hypoxia inducible factor-1α [36].
mTORC2 consists of 7 proteins and different studies have
found that, when activated, it phosphorylates kinases. In particu-
lar, it is worth mentioning the direct activation of AKT through
phosphorylation at its hydrophobic motif (Ser473), thus promot-
ing all AKT-mediated downstream implications that ultimately
lead to cell growth [36].
Importantly, mTORC1, but not mTORC2, is inhibited by rapa-
mycin. In addition, mTORC2 exerts a positive feedback activation
on AKT.Alterations of the PI3K/AKT/mTOR Pathway
in Ovarian Cancer
The PI3K/AKT/mTOR pathway is activated in approximately 70%
of ovarian cancer cases, thus promoting cellular growth, prolifera-
tion and cell survival through intricate series of hyperactive signal-
ing cascades [39]. Its activation is associated with higher invasive
and migratory capacities even within heterogeneous cell subpo-
pulations co-existing within human ovarian cancer, thus making
the PI3K/AKT/mTOR pathway a potential predictor of invasiveness
for ovarian tumor cells [40].
Different mechanisms can persistently activate the mTor path-
way in cancer. Other than upstream input, somatic activating mu-
tations in the PIK3CA gene (encoding for the p110 catalytic sub-
unit) were found in 12% of ovarian cancer cases [41].
From an oncogenic point of view, it has been recently well es-
tablished that ovarian cancer represents a heterogeneous group
of different neoplasms, each characterized by distinct etiology
and phenotype [42]. In particular, Kurman et al. with their recent
dichotomic classification of ovarian cancer subtypes, highlighted
that type I tumors (mainly low-grade serous, low-grade endome-
trioid, mucinous, clear cells and Brenner carcinomas) develop
from benign extraovarian lesions implanting on the ovary, which
can successively transform into malignant lesions, whereas many
type II carcinomas (including high-grade serous ovarian cancers)
develop from intraepithelial carcinomas in the fallopian tube
(STIC, serous tubal intraepithelial carcinomas) and rapidly dissem-
inate to the ovary and extraovarian sites [43]. The different sub-
types of ovarian cancers present since their origin with distinct ge-
netic mutational panels [42,43].
High-grade serous ovarian cancer reports rare mutations of
the PI3K/Akt, in contrast to clear cell ovarian cancer (OCCC) and
endometrioid adenocarcinoma. Gain of function PIK3CA-muta-
tion has been suggested to occur in 30–40% of ovarian clear cell
carcinomas and in 12–20% of endometroid ovarian carcinomas
[44]. Mutations of the PIK3R1 gene encoding for the p85 regula-
tory subunit were found in 3.8% of ovarian cancer [45]. Other in-
trinsic mechanisms involved in PI3K/Akt/mTor hyperactivation in
cancer include: mutations or amplifications in one of the AKT iso-
forms, loss of the negative regulator PTEN, loss or inactivating
mutations in the tumor suppressors like TSC or LKB1 [30], or even
loss of the INPP4B, which was found in up to 39% of ovarian cancer
[34]. As a consequence, there is a gain in cell growth and prolifer-Gasparri ML et al. PI3K/AKT/mTOR Pathway in… Geburtsh Frauenheilk 2017; 77: 1095–1103ation, angiogenesis and therefore a promotion of cell transforma-
tion and/or progression.
Inhibition of PI3K/Akt/mTor in mice models was found to delay
tumor growth and prolong survival [46], providing practical proof
of the importance of this pathway in oncogenesis and/or onco-
progression of ovarian cancer and of its possible targeting as new
therapeutic strategy. Inhibitors of the PI3K/AKT/mTOR pathway
can be classified into 4 main categories: mTor inhibitors, PI3K in-
hibitors, dual mTor/PI3K inhibitors and AKT inhibitors.mTor Inhibitors
Rapamycin (sirolimus) is a chemical compound initially discovered
in the 1970s as a product of Streptomyces Hygroscopicus bacteria
growing in a soil sample originating from Easter Island [47]. It was
initially developed as an antifungal and immunosuppressive drug
but its anticancer potential was observed during the last decade
[48]. Rapamycin and its analogues perform their inhibitory activ-
ity towards mTor, by initially binding the intracellular protein
FK506-binding protein 12 (FKBP12). The rapamycin-FKBP12 com-
plex interacts with the FKBP12-rapamycin-binding domain (FRB)
of mTor, causing an allosteric transformation that ultimately leads
to the mTor kinase activity inhibition [32,35,49].
The lack of subsequent phosphorylation of S6K1 e 4EBP1 pre-
vents CDK activation, resulting in cell cycle arrest in G1/S [50].
Early clinical studies of mTOR inhibitors in cancer have shown
promising results [37]. The most studied mTor inhibitors in ovar-
ian cancer are: temsirolimus, everolimus, and ridaforolimus.
▶ Fig. 1 shows the PI3K/Akt/mTor pathway and the effects of
mTOR-inhibitors.
Temsirolimus
The Gynecologic Oncology Group (GOG) conducted a phase II
clinical trial investigating temsirolimus as single agent in 60 pa-
tients affected by recurrent epithelial ovarian and primary perito-
neal cancers. Out of 54 eligible patients, 24.1% progressed after
at least 6 months and 9.3% achieved a partial response. Adverse
events reported were fatigue, gastrointestinal and metabolic al-
terations including 1 case of grade 3 renal failure and grade 4 pul-
monary embolism [51]. Notably, tumor expression of cyclin D1
appeared to be associated with higher p4EBP1 and a greater like-
lihood of prolonged PFS and overall survival [51].
Fifteen gynecological cancer patients were enrolled by Temkin
et al. in a trial investigating the effect of combined intravenous in-
fusions of topotecan and temsirolimus (1mg/m2 and 25mg, re-
spectively) once daily on days 1, 8 and 15 of a 28 day cycle. Tem-
sirolimus alone was infused on day 22 of each cycle [52]. Temsi-
rolimus was dose reduced to 15mg in some cases due to grade 3
thrombocytopenia. Nine out of 11 patients (81.8%) reported sta-
ble disease throughout the almost 2-year study period.
Another regimen of weekly Temsirolimus was tested in Saita-
ma, Japan, in patients with recurrent ovarian clear cell carcinoma,
previously treated with at least 4 different therapy regimens.
Among five evaluable patients, partial response was observed in
one case (20%) and stabilized disease was seen in another case
(20%). There were no toxicities greater than grade 3, and no case1097
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▶ Fig. 1 PI3K/Akt/mTor pathway and effects of mTOR-inhibitors. Different signaling cascades have been shown to modulate mammalian target of
rapamycin (mTOR). Growth factor mediated intracellular signaling triggered PDPK1 to phosphorylate and activate PKB/AKT. AKT directly phospho-
inhibited TSC2 which consequently resulted in activation of mTOR via RHEB resulting in phosphorylation of protein S6 kinase beta-1 (S6K1). Newer
treatment strategies should focus on inhibition of mTORC1 and mTORC2 multi-proteins assemblies and on treatments that combine mTOR inhib-
itors with different interconnected pathway inhibitors.
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[53].
The combination of carboplatin, paclitaxel and temsirolimus in
patients with advanced solid tumors has been evaluated in the at-
tempt to assess safety, tolerability and antitumor activity by Koll-
mannsberger et al. [54]. Among 38 enrolled patients, 6 (16%)
were affected by ovarian cancer. The phase I study concluded that
the recommended dose of the regimen should be carboplatin
AUC 5mg/ml/min and paclitaxel 175mg/m2, both given on day
1, plus temsirolimus 25mg on days 1 and 8. This regimen was well
tolerated. In 17/38 patients, partial response with a median PFS of
7.4 months was observed, while 49% of patients had stable dis-
ease. Among the 6 included ovarian cancer patients, 3 reported a
partial response and 3 experienced disease stabilization. Grade 4
adverse effects consisted of myelotoxicity and fatigue.
More recently, tesmirolimus was tested in a Phase Ib study in
combination with pegylated liposomal doxorubicin (PLD) on ad-
vanced breast, endometrial and ovarian cancer patients [55].
Twenty patients received weekly escalating dose of temsirolimus
combined with PLD 30 or 40mg/m2 once per month. Eleven pa-1098 Gtients (55%) were affected by OC. The recommended Phase II
dose was found to be temsirolimus 15mg plus PLD 40mg/m2.
Three patients (two with ovarian cancer) reported durable partial
response lasting 10.1, 12.7 and 13.7 months. Further 8 patients
(two with ovarian cancer) had a long lasting stable disease (me-
dian 6.4 months). Most frequent adverse events were nausea, fa-
tigue, mucositis, and skin toxicity.
Another recent combination of solely target therapies con-
sisted of bevacizumab plus temsirolimus administered on ad-
vanced gynecologic tumors [56]. Bevacizumab 2.5–15mg/kg
was given on day 1 together with temsirolimus 5–25 on day 1, 8,
15 in three-weekly treatment cycles. Twenty-two patients out of
41 (54%) had ovarian cancer. Two out of 22 ovarian cancer pa-
tients reported a partial response whereas further 4 ovarian
cancer patients experienced disease stabilization lasting over
6 months. Most common grade 3/4 treatment-related toxicities
were thrombocytopenia (10%) and fatigue (7%).
In 2016, the AGO-study group published a Phase II study of
weekly temsirolimus 25mg administered to refractory/resistant
ovarian cancer and advanced/recurrent endometrial carcinomaasparri ML et al. PI3K/AKT/mTOR Pathway in… Geburtsh Frauenheilk 2017; 77: 1095–1103
patients [57]. Half of the patients enrolled (22/44) had ovarian
cancer. After 8 weeks of treatment, partial response and stable
disease were 1 (4.5%) and 7 (31.8%), respectively, among the
ovarian cancer population. Most common severe toxicities were
gastrointestinal disorders and one patient reported a grade 4
ileus.
Everolimus
A phase I study carried out on 32 patients affected by solid tumors
treated with a combination regimen of five milligrams three times
weekly of everolimus plus panitumumab at 4.8mg/kg and bevaci-
zumab at 10mg/kg every 2 weeks resulted to be safe and toler-
able and showed a moderate clinical activity [58]. Four out of 32
patients (12.5%) had recurrent ovarian cancer. Three of them
showed clinical response lasting at least 6 months after the treat-
ment. The most common grade 3–4 toxicities were electrolytic
disorders (35%), blood hypertension (16%), skin rush (16%) and
mucositis (13%).
A very recent study about the everolimus effects was carried
out on ovarian cancer mouse models with the aim of assessing
the relationship between everolimus efficacy and obesity [59].
The study hypothesis was justified by the observation that obesity
leads to hyperactivation of the mTOR pathway in epithelial tis-
sues, thus suggesting that mTOR inhibitors may be particularly ef-
fective in obese cancer patients [60]. Everolimus treatment re-
sulted in the inhibition of tumor growth in both obese and lean
mouse models but the analysis of the metabolic profile revealed
that everolimus was able to alter tumor metabolism through dif-
ferent metabolic pathways between the two groups, thus sug-
gesting that everolimus may act as antitumor agent through dif-
ferent ways among obese and lean ovarian cancer individuals.
Other mTor inhibitors
Another aspect to consider, when referring to mTor inhibitors, is
their capacity to significantly sensitize Taxol-induced anti-ovarian
cancer cell activity in vitro and in vivo, without causing apparent▶ Table 1 Ongoing trials on mTor inhibitors in ovarian cancer.
ClinicalTrials.Gov
Identification
number
Phase
study
Population Scheduled
NCT01031381 II Recurrent ovarian,
peritoneal and fallopian
tube cancer
Everolimus +
bevacizumab
NCT02188550 II Recurring/platinum
resistant ovarian/endo-
metrial cancer
Everolimus +
letrazole
NCT02283658 II Relapsed hormone re-
ceptor positive ovarian,
fallopian tube or primary
peritoneal carcinomas
Everolimus +
letrazole
NCT00886691 II Ovarian cancer, fallopian
tube cancer, primary
peritoneal cavity cancer
Everolimus and
bevacizumab
Gasparri ML et al. PI3K/AKT/mTOR Pathway in… Geburtsh Frauenheilk 2017; 77: 1095–1103toxicities, as recently described by Zhang et al. in their study in-
volving WYE-132, a mTORC1/2 dual inhibitor [61]. Furthermore,
it appears that mTor inhibitors would have synergistic effects
while used in combination with other target therapies, in particu-
lar the Ras/Raf/MEK pathway in endometrial carcinoma [62],
which might justify assessment of the combined target therapies
treatment effectiveness in ovarian cancer as well. However, in en-
dometrial cancer recurrence setting, the clinical application of
these drugs is currently controversial [63]. Another study con-
ducted by Hussein et al., where a second-generation mTor inhib-
itor, Torin2 was tested, resulted in the inhibition of tumor cell via-
bility and induction of apoptosis in epithelial ovarian cancer. In ad-
dition, this study found that combination in vivo of Torin2 and cis-
platin synergistically inhibited tumor growth in nude mice, con-
firming the hypothesis that mTor inhibitors might serve as single
agent therapies as well as in combination with other treatment
options, acting either as synergic agents or sensitizing ones [61,
64]. In this scenario, it was also recently shown that the combina-
tion of PIK3 inhibitor BKM120 with PARP inhibitor olaparib re-
sulted in reduced proliferation, survival and invasion in different
ovarian cancer cell lines harboring PIK3CA mutations and in a sig-
nificantly decreased BRCA1 expression in SKOV3 ovarian cancer
cells [65].
Despite promising results in several studies, larger scale inves-
tigations are needed for a better characterization of the mTor in-
hibitors properties as antitumor agents. Up to date, no phase III
trials have been reported on these drugs. ▶ Table 1 summarizes
the ongoing clinical trials involving mTor inhibitors in ovarian can-
cer. Preliminary results presented at the ASCO Meeting 2016 of
the ongoing Phase II clinical trial investigating the effects of the
combination “bevacizumab plus everolimus” in recurrent ovarian
cancer patients (NCT01031381) [66], revealed that 14/50 (28%)
patients were progression-free at 6 months (95% CI 16.67–
42.71%), with with 5 (0.65%) grade 4 and 66 (8.64%) grade 3 tox-
icities, mostly consisting in oral mucositis, fatigue, abdominalCourse Primary outcome
Everolimus 10mg orally daily continuously
Bevacizumab IV once every 14 days
6 months PFS
Everolimus: 10mg orally daily
Letrazole: 2.5 mg orally daily, 28 days cycle
Evaluation every 3 cycles
Tumor response
to treatment
Oral everolimus and oral letrozole on days 1–28 OS and PFS
Bevacizumab IV over 30–90minutes on
days 1 and 15
Oral Everolimus once daily on days 1–28
PFS
Continued next page
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▶ Table 1 Ongoing trials on mTor inhibitors in ovarian cancer. (Continued)
ClinicalTrials.Gov
Identification
number
Phase
study
Population Scheduled Course Primary outcome
NCT01281514 I Relapsed ovarian epi-
thelial, fallopian tube, or
peritoneal cavity cancer
Everolimus,
carboplatin
and PLD
Carboplatin (IV) on day 1
PLD (IV) on day 1
Everolimus orally once daily on days 1–28.
28 days cycle repeated for 6 courses
Safety and
feasibility
NCT00982631 Ib Advanced recurrent
ovarian endometrial and
breast cancer
Temsirolimus/
PLD
28 days cycle
Temsirolimus iv once weekly in a dose escalating
study scheme
MTD, pharmaco-
kinetic parameters
NCT01460979 II Platinum-refractory ovar-
ian carcinoma or advanced
endometrial carcinoma
Temsirolimus 25mg weekly
IV
until progression
Evaluation every 8 weeks
Activity, tolerability
and safety of the
drug
NCT01196429 II FIGO stage III–IV (first line)
Clear cell ovarian cancer
Temsirolimus,
carboplatin,
and paclitaxel
Paclitaxel IV over 3 hours and
Carboplatin IV over 30 minutes on day 1 and
Temsirolimus IV on days 1 and 8
3 weeks cycle repeated for 6 courses
OS and PFS
NCT01010126 II FIGO stage III–IV endo-
metrial cancer, ovarian
cancer, fallopian tube
cancer, uterine corpus
cancer
Temsirolimus
and
bevacizumab
Temsirolimus IV on days 1, 8, 15, and 22
Bevacizumab IV over 30–90minutes on
days 1 and 15
28 days cycles. Courses repeat in absence of dis-
ease progression
Progression free
survival and tumor
response rate
NCT01065662 I/Ib Recurrent/refractory
gynecological malig-
nancies
Temsirolimus
and cediranib
Temsirolimus on days 1, 8, 15 and 22 of each cycle
Cediranib orally daily
28 days cycle
Maximum tolerated
dose
NCT01155258 I Advanced solid tumors Temsirolimus
and vinorelbine
28 days cycles. Courses repeat in absence
of disease progression
Temsirolimus IV over 30–60minutes on
days 1, 8, 15, and 22
Vinorelbine IV over 5–10minutes on days 1
and 15
Tumor response
rate and maximum
tolerated dose
NCT01256268 I Recurrent or metastatic
endometrial cancer/
recurrent or metastatic
ovarian cancer
Carboplatin,
paclitaxel and
ridaforolimus
Ridaforolimus 20–40mg
Paclitaxel 175mg/m2 IV and
Carboplatin (AUC 5 to 6) on day 1 of each
3 week cycle
Treatment will continue until disease progression
or adverse events
Preliminary efficacy
and maximum
tolerated dose
NCT01281514 I Recurrent ovarian,
fallopian tube or peritoneal
cancer
Carboplatin +
PLD +
everolimus
28 days cycles for 6 months
Carboplatin intravenously IV + PLD IV on day 1 +
everolimus orally once daily on days 1–28.
Maximum tolerated
dose (MTD)
Safety and
tolerability
Efficacy
NCT02208375 I/II Recurrent endometrial,
triple negative breast,
ovarian, primary peri-
toneal, or fallopian tube
cancer
Olaparib +
mTORC1/2
inhibitor
AZD2014
or
AKT inhibitor
AZD5363
Monthly cycles
Olaparib + AZD2014 (continuous or intermittent
dosing)
Or Olaparib + AZD5363 (intermittent dosing)
Treatment will continue until disease progression
or adverse events
Tumor response
rate and maximum
tolerated dose
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pain, diarrhea, nausea and hypertension. Clinical responses were
stable disease in the great majority of cases.Problematic Aspects Regarding
mTor Inhibitors
The precise mechanism of drug resistance remains unknown. Loss
of the established negative feedback to the drug seems to be in-
volved in the resistance mechanisms.
The selective affinity of mTor inhibitors for mTORC1 and lack of
suppression of mTORC2 have been suggested as a mechanism of
drug resistance.
Indeed, mTORC2 engages in an AKT-activation loop in re-
sponse to mTORC1 inhibition [38]. New inhibitors that target
both mTORC1 and mTORC2, or even PI3K inhibitors in combined
regimens could be the right way of overcoming drug resistance.
Another crucial aspect of the application of mTor inhibitors in
ovarian cancer is the selection of correct patients, since it seems
that rapamycin and its analogues are more effective in tumors
that express high activity of PI3K/AKT/mTORC1 pathways such as
ovarian clear cell carcinoma and endometrioid ovarian cancer
[49]. Additionally, patients presenting PIK3CA alterations respond
better than patients with functioning PIK3CA [39].
Furthermore, a comprehensive identification of the toxicity
profile of ovarian cancer patients treated with mTOR inhibitors is
still strongly needed. Larger studies on breast cancer patients sug-
gest that the most common adverse events of mTOR inhibitors
include stomatitis (all grades: approximately 60%), noninfectious
pneumonitis (15%), rash (40%), hyperglycemia (15%), and immu-
nosuppression (40%) [67]. Future results derived from the cur-
rently ongoing phase II clinical trials on the use of mTOR inhibitors
in ovarian cancer will better elucidate this crucial aspect, pivotal
for establishing the integration of these compounds into the clin-
ical practice of ovarian cancer treatment.Conclusions
PI3K/AKT/mTORC1 pathway inhibitors constitute a group of new
target therapies for the treatment of ovarian cancer, given the
highly expressed activity of this pathway in the pathogenesis and
progression of ovarian carcinoma. Promising preliminary results in
phase I and II trials encourage further studies. However, no phase
III trials on ovarian cancer patients have been reported yet.
A selection of the cancer population that could mostly benefit
from these new drugs and better understanding of how to inte-
grate these new medications are pivotal for improving the current
management of ovarian cancer.
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